TGTX | TG Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	36.50 - 39.61
52 Week Range	12.93 - 43.32
Beta	2.16
Implied Volatility	94.43%
IV Rank	83.27%
Day's Volume	3,626,938
Average Volume	2,641,247
Shares Outstanding	157,071,000
Market Cap	6,193,309,530
Sector	Healthcare
Industry	Biotechnology
IPO Date	2010-05-03

Valuation
Profitability
Growth
Health
P/E Ratio	262.87
Forward P/E Ratio	-6.00
EPS	0.15
1YR Price Target	19.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	319
Country	USA
Website	TGTX

TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor.

TGTX's peers: AGEN, ATNM, AUPH, AVXL, AXSM, BCRX, BTAI, CPRX, ETNB, EXEL, GERN, IBRX, MDGL, NVO, SAVA, ICPT, TERN, HEPA, VKTX, AKRO, RETA, XFOR, PDSB

*Chart delayed

Analyzing fundamentals for TGTX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is passable. For more detailed analysis please see TGTX Fundamentals page.

Watching at TGTX technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on TGTX Technicals page.